Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

CIO July 15, 2001 Stephanie Overby	Iceland's Dilemma: Privacy vs. Progress A small Icelandic startup has been granted a 12-year license to create and manage a database of the entire nation's medical and genetic records. Can it make medical history without violating patient privacy?
Bio-IT World September 2005 Mark D. Uehling	Kings of Genes and Data The speed by which things move at Iceland's deCODE supports the company's claim that it is not only reconnecting the bifurcated worlds of drug discovery and clinical research - it is also internally cross-pollinating ideas between those two realms.
Bio-IT World October 9, 2002 Malorye Branca	The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response.
Bio-IT World May 2006 Kevin Davies	Decoding the Genetics of Common Disease Icelandic biopharma deCODE Genetics' Kari Stefansson says his company's search for genes underlying common diseases is not only pushing promising new drug candidates into the clinic but also revealing new insights into the very basis of common disease.
CIO April 1, 2003 Pat McCaffrey	Iceland's Database Tussle Biotechnology company DeCode Genetics wants to establish and commercialize a database of the personal medical records of all the citizens of Iceland. But delays in obtaining government approval, opposition from doctors and financial struggles at DeCode are raising doubts about the project's viability
Bio-IT World February 10, 2003 Mark D. Uehling	Decoding Estonia The former Soviet republic aims to use IT and culture to build a national gene database. It is modestly funded but is already being noticed by scientists and industry.
Bio-IT World February 18, 2004	The Quest for Complex Genes Genetic sleuths are homing in on genes for complex diseases with the help of new, and some not so new, tools and strategies.
Fast Company November 2009 David H. Freedman	The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens.
Bio-IT World September 9, 2002 Malorye Branca	The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems.
Chemistry World July 2010 Anna Lewcock	Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.
Chemistry World July 2010 Hayley Birch	Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade.
Bio-IT World July 2005 Kevin Davies	Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference.
Bio-IT World June 17, 2004 Michael A. Goldman	A Hip Approach to Gene Hunting IntegraGen defines the genetic blueprint of complex human diseases and delivers validated disease markers and therapeutic targets for a better diagnosis and a causal treatment of common diseases, based on its unique genomic analysis expertise.
Salon.com May 1, 2000 Arthur Allen	Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic.
The Motley Fool March 18, 2008 Brian Orelli	The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will?
American Journal of Nursing October 2009	Pharmacogenomics: Personalizing Drug Therapy Pharmacogenomics is a rapidly growing field of research into the ways in which genetic variation affects drug response.
Bio-IT World February 11, 2005 Kevin Davies	The Galileo Code In searching 400 years of French-Canadian history for genetic clues to diseases among Quebec's founding population, Genizon BioSciences -- formerly Galileo Genomics -- is rapidly becoming the bio-IT company du jour.
BusinessWeek September 5, 2005 Capell & Arndt	Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
The Motley Fool August 27, 2004 W.D. Crotty	deCODE This deCODE genetics' auditor's resignation provides a buying opportunity for those who buy story stocks.
Bio-IT World January 12, 2004 Karen Hopkin	High-Tech Search for the Fountain of Youth Dramatic advances may help biotechs develop drugs that slow aging.
Wired July 2006 Kevin Kelleher	Personalize It While Adidas offers customized shoes for your feet, the pharmaceutical industry is moving toward personalizing drugs based on your genes.
The Motley Fool May 28, 2010 Brian Orelli	Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree.
BusinessWeek May 9, 2005	A Genome Pioneer Looks Forward Dr. Francis Collins discusses the end of the Human Genome Project and says an "outpouring of discoveries" is coming soon.
Pharmaceutical Executive November 1, 2011 Elizabeth O. Coulton	Clinical Trial Issues Not Just Black and White The selection of clinical trial participants must meld with the changing demographics of America if industry is to improve medicines that work for patients.
Bio-IT World July 11, 2002 Mike Fitzgerald	Funding the Future Investor G. Steven Burrill, CEO of Burrill & Company, helps biotech companies fulfill their potential. He talked recently about his view of the bio-IT field.
Bio-IT World December 10, 2002	Craig Venter Unvarnished (part II) The former Celera CEO covers privacy, ESTs, and his new research institutes.
Managed Care November 2006 Maureen Glabman	Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part.
BusinessWeek October 1, 2007 Conrad Wilson	A Dream Team Of Drugs And Diagnosis? If a deal is struck, a Roche-Ventana team could help launch a medical revolution.
BusinessWeek April 22, 2010 Rob Waters	Gene Therapy Takes a Turn for the Better Researchers and investors are heartened by advances in gene therapy. Analysts say revenues are still several years off, however.
Bio-IT World March 2006	Special Show Preview: It's Showtime! Highlights of the upcoming fifth annual Bio IT World conference: Decoding the Genome... The Six-Figure Sequence... E-Clinical Futures... etc.
Fast Company January 2002 George Anders	Roche's New Scientific Method How does a giant pharmaceutical company reckon with genomics technology? By making a fresh start in how it recruits its scientists, manages projects, and uses computers. Here's how the Roche Group is reinventing how it invents...
Scientific American June 2009 Melinda Wenner	Genetic Copy Variations and Disease A new sense for how variable numbers of genes cause disease.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
Pharmaceutical Executive September 1, 2012 Roy F. Waldron	Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector?
The Motley Fool June 7, 2011 Brian Orelli	Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal.
BusinessWeek June 13, 2005 John Carey	The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications.
American Family Physician August 1, 2005 Wattendorf & Hadley	Family History: The Three-Generation Pedigree The three-generation pedigree provides a pictorial representation of diseases within a family and is the most efficient way to assess hereditary influences on disease.
Nurse Practitioner August 2009 Linda A. Howe	Pharmacogenomics and management of cardiovascular disease Prior to the completion of the Human Genome Project in 2003, individual responses to medications were usually termed idiosyncrasies. Ethnic differences were not usually seen as genetic variants, as is the case today.
The Motley Fool August 12, 2009 Brian Orelli	The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing.
Bio-IT World May 7, 2002 John Dodge	Big Pharmas Are Dinosaurs Not much escapes Nathan Myhrvold's predatory intellect. His company, Intellectual Ventures, is on the prowl for more good ideas. We spoke with the voluble Myhrvold to find out why he is so high on biotech.
Bio-IT World November 12, 2002 Sue Mayer	Are Gene Patents in the Public Interest? Two recent studies from Britain argue against the unbridled patenting of genes and raise tough ethical questions.
Pharmaceutical Executive September 1, 2012 Al Topin	Doctors' Words No Longer Gospel In the digital age, physicians don't call the shots when it comes to healthcare guidance. Marketers must appeal to multiple sources in seeking ways to garner patient adherence and loyalty.
HHMI Bulletin Nov 2010	Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
Bio-IT World February 2006	News Blast Hit-to-Lead... Whole Genome... Gleevec Resistance...
The Motley Fool February 2, 2010 Brian Orelli	Shaking Up the Biotech Industry A judge will decide if genes are patentable or not.
Bio-IT World August 13, 2003 Kevin Davies	Playing by Aussie Rules GTG's Mervyn Jacobson discusses the controversial patenting of non-coding DNA.
Wired November 2002 David Ewing Duncan	DNA as Destiny DNA is the book of life. It's also the book of death. In the future we'll all be read cover to cover. Here's what it's like to take the world's first top-to-bottom gene scan.
Bio-IT World July 11, 2002 Kevin Davies	Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go.